PortfoliosLab logoPortfoliosLab logo
LLY vs. HIMS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

LLY vs. HIMS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eli Lilly and Company (LLY) and Hims & Hers Health, Inc. (HIMS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, LLY achieves a 0.72% return, which is significantly higher than HIMS's -15.28% return.


LLY

1D
1.37%
1M
11.64%
YTD
0.72%
6M
4.73%
1Y
44.70%
3Y*
35.56%
5Y*
41.13%
10Y*
32.66%

HIMS

1D
0.00%
1M
0.88%
YTD
-15.28%
6M
-25.79%
1Y
-49.74%
3Y*
45.13%
5Y*
14.51%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

LLY vs. HIMS - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
LLY
Eli Lilly and Company
0.72%40.25%33.30%60.91%34.26%66.08%31.04%19.20%
HIMS
Hims & Hers Health, Inc.
-15.28%34.28%171.69%38.85%-2.14%-55.14%47.47%1.02%

Correlation

The correlation between LLY and HIMS is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.04

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (All Time)
Calculated using the full available price history since Sep 16, 2019

0.13

The correlation between LLY and HIMS shifts across timeframes, from 0.04 (1 year) to 0.14 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

LLY:

$966.48B

HIMS:

$6.28B

EPS

LLY:

$28.14

HIMS:

-$0.05

PS Ratio

LLY:

13.41

HIMS:

2.85

PB Ratio

LLY:

30.98

HIMS:

14.08

Total Revenue (TTM)

LLY:

$72.25B

HIMS:

$2.37B

Gross Profit (TTM)

LLY:

$59.75B

HIMS:

$1.70B

EBITDA (TTM)

LLY:

$32.97B

HIMS:

$16.04M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

LLY vs. HIMS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LLY
LLY Risk / Return Rank: 7272
Overall Rank
LLY Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
LLY Sortino Ratio Rank: 7070
Sortino Ratio Rank
LLY Omega Ratio Rank: 7171
Omega Ratio Rank
LLY Calmar Ratio Rank: 7373
Calmar Ratio Rank
LLY Martin Ratio Rank: 7474
Martin Ratio Rank

HIMS
HIMS Risk / Return Rank: 2020
Overall Rank
HIMS Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
HIMS Sortino Ratio Rank: 2222
Sortino Ratio Rank
HIMS Omega Ratio Rank: 2222
Omega Ratio Rank
HIMS Calmar Ratio Rank: 1717
Calmar Ratio Rank
HIMS Martin Ratio Rank: 1919
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LLY vs. HIMS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Hims & Hers Health, Inc. (HIMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


LLYHIMSDifference
Sharpe ratioReturn per unit of total volatility

+1.71

Sortino ratioReturn per unit of downside risk

+2.10

Omega ratioGain probability vs. loss probability

1.24

0.96

+0.28

Calmar ratioReturn relative to maximum drawdown

1.90

-0.64

+2.54

Martin ratioReturn relative to average drawdown

4.73

-1.06

+5.78

LLY vs. HIMS - Sharpe Ratio Comparison

The current LLY Sharpe Ratio is 1.19, which is higher than the HIMS Sharpe Ratio of -0.52. The chart below compares the historical Sharpe Ratios of LLY and HIMS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


LLYHIMSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.19

-0.52

+1.71

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

1.26

0.18

+1.09

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

1.09

Sharpe Ratio (All Time)

Calculated using the full available price history

0.57

0.22

+0.36

Drawdowns

LLY vs. HIMS - Drawdown Comparison

The maximum LLY drawdown since its inception was -68.24%, smaller than the maximum HIMS drawdown of -87.29%. Use the drawdown chart below to compare losses from any high point for LLY and HIMS.


Loading charts...

Drawdown Indicators


LLYHIMSDifference

Max Drawdown

Largest peak-to-trough decline

-68.24%

-87.29%

+19.05%

Max Drawdown (1Y)

Largest decline over 1 year

-23.64%

-78.06%

+54.42%

Max Drawdown (3Y)

Largest decline over 3 years

-34.48%

-78.88%

+44.40%

Max Drawdown (5Y)

Largest decline over 5 years

-34.48%

-79.74%

+45.26%

Max Drawdown (10Y)

Largest decline over 10 years

-34.48%

Current Drawdown

Current decline from peak

-4.26%

-59.98%

+55.72%

Average Drawdown

Average peak-to-trough decline

-19.22%

-43.19%

+23.97%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.49%

47.08%

-37.59%

Volatility

LLY vs. HIMS - Volatility Comparison

The current volatility for Eli Lilly and Company (LLY) is 9.16%, while Hims & Hers Health, Inc. (HIMS) has a volatility of 25.84%. This indicates that LLY experiences smaller price fluctuations and is considered to be less risky than HIMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


LLYHIMSDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.16%

25.84%

-16.68%

Volatility (6M)

Calculated over the trailing 6-month period

26.81%

66.58%

-39.77%

Volatility (1Y)

Calculated over the trailing 1-year period

37.88%

95.97%

-58.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

32.79%

83.37%

-50.58%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

30.14%

77.20%

-47.06%

Dividends

LLY vs. HIMS - Dividend Comparison

LLY's dividend yield for the trailing twelve months is around 0.60%, while HIMS has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
HIMS
Hims & Hers Health, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.60%0.56%0.67%0.78%1.07%1.23%1.75%1.96%1.94%2.46%2.77%2.37%

Financials

LLY vs. HIMS - Financials Comparison

This section allows you to compare key financial metrics between Eli Lilly and Company and Hims & Hers Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B20222023202420252026
19.80B
608.10M
(LLY) Total Revenue
(HIMS) Total Revenue
Values in USD except per share items

LLY vs. HIMS - Profitability Comparison

The chart below illustrates the profitability comparison between Eli Lilly and Company and Hims & Hers Health, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

65.0%70.0%75.0%80.0%85.0%20222023202420252026
79.0%
65.3%
Portfolio components
LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.

HIMS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a gross profit of 396.79M and revenue of 608.10M. Therefore, the gross margin over that period was 65.3%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.

HIMS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported an operating income of -78.32M and revenue of 608.10M, resulting in an operating margin of -12.9%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.

HIMS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a net income of -92.12M and revenue of 608.10M, resulting in a net margin of -15.2%.


Frequently Asked Questions


LLY and HIMS have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

HIMS has higher volatility (25.84%) compared to LLY (9.16%). In terms of maximum drawdown, LLY dropped -68.24% vs HIMS's -87.29%.

LLY currently has the higher Sharpe Ratio (1.19 vs -0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for LLY and HIMS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer